Trial reportMolecular psychiatry2016
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.
Trial report in Molecular psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 136 papers, 15 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Omega-3 Fatty Acids for MDD With High Inflammation: A Personalized Approach
Do Omega-3 Fatty Acids Have an Antidepressant Effect in Patients With Signs of Peripheral Inflammation?
Who cites it
136 citing papers in PubMed, 15 syntheses or guidelines pooled it, 263 citations in OpenAlex.
- Understanding the research landscape of over-the-counter herbal products, dietary supplements, and medications evaluated for depressive symptoms in adults: a scoping review.Frontiers in pharmacology · 2025Pooled it
- Omega-3 fatty acid supplementation for depression in children and adolescents.The Cochrane database of systematic reviews · 2024Pooled it
- Nutraceuticals in Psychiatric Disorders: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Predictors of successful anti-inflammatory drug trials in patients with schizophrenia: A meta-regression and critical commentary.Brain, behavior, and immunity · 2023Pooled it
- Omega-3 fatty acids for depression in adults.The Cochrane database of systematic reviews · 2021Pooled it
- Pooled it
- Augmenting Clinical Interventions in Psychiatric Disorders: Systematic Review and Update on Nutrition.Frontiers in psychiatry · 2021Pooled it
- Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?International journal of molecular sciences · 2019Pooled it
- Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels.Psychological medicine · 2019Pooled it
- Efficacy of omega-3 PUFAs in depression: A meta-analysis.Translational psychiatry · 2019Pooled it
- Adjunctive nutrients in first-episode psychosis: A systematic review of efficacy, tolerability and neurobiological mechanisms.Early intervention in psychiatry · 2018Pooled it
- Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and Biological Studies.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Pooled it
- Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression.The British journal of psychiatry : the journal of mental science · 2016Pooled it
- Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.Translational psychiatry · 2016Pooled it
- Omega-3 fatty acids for depression in adults.The Cochrane database of systematic reviews · 2015Pooled it
- Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Trial
- Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis.Molecular psychiatry · 2021Trial
- Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial.Molecular psychiatry · 2021Trial
- Secondary data analysis investigating effects of marine omega-3 fatty acids on circulating levels of leptin and adiponectin in older adults.Prostaglandins, leukotrienes, and essential fatty acids · 2021Trial
- Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation.Prostaglandins, leukotrienes, and essential fatty acids · 2021Trial
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
This study explores whether inflammatory biomarkers act as moderators of clinical response to omega-3 (n-3) fatty acids in subjects with major depressive disorder (MDD). One hundred fifty-five subjects with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) MDD, a baseline 17-item Hamilton Depression Rating Scale (HAM-D-17) score ⩾ 15 and baseline biomarker data (interleukin (IL)-1ra, IL-6, high-sensitivity C-reactive protein (hs-CRP), leptin and adiponectin) were randomized between 18 May 2006 and 30 June 2011 to 8 weeks of double-blind treatment with eicosapentaenoic acid (EPA)-enriched n-3 1060 mg day(-1), docosahexaenoic acid (DHA)-enriched n-3 900 mg day(-1) or placebo. Outcomes were determined using mixed model repeated measures analysis for 'high' and 'low' inflammation groups based on individual and combined biomarkers. Results are presented in terms of standardized treatment effect size (ES) for change in HAM-D-17 from baseline to treatment week 8. Although overall treatment group differences were negligible (ES=-0.13 to +0.04), subjects with any 'high' inflammation improved more on EPA than placebo (ES=-0.39) or DHA (ES=-0.60) and less on DHA than placebo (ES=+0.21); furthermore, EPA-placebo separation increased with increasing numbers of markers of high inflammation. Subjects randomized to EPA with 'high' IL-1ra or hs-CRP or low adiponectin ('high' inflammation) had medium ES decreases in HAM-D-17 scores vs subjects 'low' on these biomarkers. Subjects with 'high' hs-CRP, IL-6 or leptin were less placebo-responsive than subjects with low levels of these biomarkers (medium to large ES differences). Employing multiple markers of inflammation facilitated identification of a more homogeneous cohort of subjects with MDD responding to EPA vs placebo in our cohort. Studies are needed to replicate and extend this proof-of-concept work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.